Nykode Therapeutics AS (VACBF,NYKD.OL), an Oslo-based clinical-stage biopharmaceutical platform, on Wednesday it reported profit in the second quarter compared with the previous year.
For the second quarter, profit came in at $859 million compared with loss of $7.39 billion in the prior year.
Operating loss narrowed to $6.68 billion from $11.79 billion in the prior year.
However, revenue for the quarter declined to $198 million from $584 million in the previous year.
On Tuesday, Nykode Therapeutics closed trading, 3.89% lesser at NOK 1.7300 on the Oslo Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.